Clinical Trial Update: Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating fixed-dose combination therapy of vildagliptin and metformin in type 2 diabetes inadequately controlled on metformin alone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Vildagliptin/metformin (vildagliptin/metformin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED